Detailed Abstract
[E-poster - Liver (Liver Disease/Surgery)]
[EP 090] Efficacy of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Hepatocellular Carcinoma: a Phase II Study
Seo Hee CHOI 1, Byung Min LEE 1, Jina KIM 1, Do Young KIM 2, Jinsil SEONG 1
1 Radiation Oncology, Yonsei Cancer Hospital, REPUBLIC OF KOREA, 2 Internal Medicine, Yonsei Cancer Hospital, REPUBLIC OF KOREA
Background : Limited evidence exists regarding stereotactic ablative radiotherapy (SABR) use for oligometastatic hepatocellular carcinoma (HCC). We aimed to prospectively investigate the efficacy and safety of SABR in patients with oligometastatic HCC.
Methods : We enrolled patients with controlled primary HCC and one to five metastatic lesions amenable to SABR. The primary endpoint was treatment efficacy defined as overall survival (OS) and progression-free survival (PFS). The secondary endpoints included time to local progression, objective response rate, disease control rate, toxicities, and quality of life (QOL), assessed using the EORTC QLQ-C30 before, and 0, 1, and 3 months after SABR.
Results : Overall, 40 consecutive patients received SABR on 62 lesions between 2021 and 2022. After a median follow-up of 15.5 months, the 2-year OS was 80%. Median PFS was 5.3 months, with 1- and 2-year rates of 21.2% and 0%, respectively. A shorter time to for oligometastatic disease from the controlled primary independently correlated with PFS (p = 0.039, hazard ratio: 2.127) alongside age, Child–Pugh class, and α-fetoprotein (p = 0.002, 0.004, 0.019). The 2-year time to local progression, objective response rate, and disease control rate were 91.1%, 75.8%, and 98.4%, respectively. Overall, 10% of the patients experienced acute toxicity, and 7.5% experienced late toxicity, with no grade 3+ toxicity. All QOL scores remained stable, whereas the patients without systemic treatments had improved insomnia and social functioning scores.
Conclusions : SABR is an effective and feasible option for oligometastatic HCC, excellently controls local tumors, and improves survival without adversely affecting QOL.
Methods : We enrolled patients with controlled primary HCC and one to five metastatic lesions amenable to SABR. The primary endpoint was treatment efficacy defined as overall survival (OS) and progression-free survival (PFS). The secondary endpoints included time to local progression, objective response rate, disease control rate, toxicities, and quality of life (QOL), assessed using the EORTC QLQ-C30 before, and 0, 1, and 3 months after SABR.
Results : Overall, 40 consecutive patients received SABR on 62 lesions between 2021 and 2022. After a median follow-up of 15.5 months, the 2-year OS was 80%. Median PFS was 5.3 months, with 1- and 2-year rates of 21.2% and 0%, respectively. A shorter time to for oligometastatic disease from the controlled primary independently correlated with PFS (p = 0.039, hazard ratio: 2.127) alongside age, Child–Pugh class, and α-fetoprotein (p = 0.002, 0.004, 0.019). The 2-year time to local progression, objective response rate, and disease control rate were 91.1%, 75.8%, and 98.4%, respectively. Overall, 10% of the patients experienced acute toxicity, and 7.5% experienced late toxicity, with no grade 3+ toxicity. All QOL scores remained stable, whereas the patients without systemic treatments had improved insomnia and social functioning scores.
Conclusions : SABR is an effective and feasible option for oligometastatic HCC, excellently controls local tumors, and improves survival without adversely affecting QOL.
SESSION
E-poster
E-Session 03/21 ALL DAY